TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.

F Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.